Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Issue 5 (4th January 2019)

• Record Type: Journal Article
• Authors: Abraham, Allistair A.; Lang, Haili; Meier, Emily Riehm; Nickel, Robert S.; Dean, Marcus; Lawal, Nurah; Speller‐Brown, Barbara; Wang, Yunfei; Kean, Leslie; Bollard, Catherine M.
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 5(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-01-04
• Subjects: hydroxyurea -- NK cells -- sickle cell disease; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27601
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Sickle cell disease (SCD) is increasingly recognized as a red blood cell disorder modulated by abnormally increased inflammation. We have previously shown that in patients with SCD not on a disease‐modifying therapy (hydroxyurea or chronic transfusions), natural killer (NK) cell numbers are increased. In the current study, we further investigated the NK cell function to determine if there was evidence of increased activation and cytotoxicity. Procedure: We conducted a cross‐sectional study of 44 patients with HbSS/HbSβ 0 thalassemia at steady state (hydroxyurea = 13, chronic transfusion = 11, no disease‐modifying therapy = 20) and 23 healthy controls. Using a fresh blood sample, NK immunophenotyping was performed as follows: NK cells (CD3 − CD56 + lymphocytes) were evaluated for makers associated with activation (NKG2D, NKp30, NKp44, and CD69) and maturity (CD57, killer immunoglobulin‐like receptors (KIR), and CD56dim). Degranulation and cytotoxicity assays were performed to evaluate NK cell function. Results: Patients with SCD who were not on disease‐modifying therapy had a higher number of NK cells with an immunophenotype associated with increased cytotoxicity (NKG2D +, NKp30 +, CD56dim +, and KIR + NK cells) compared with healthy controls and patients on hydroxyurea. NK cells from SCD patients not on disease‐modifying therapy demonstrated significantly increased cytotoxicity (measured by assaying NK cell killing of the K562 cell line) compared with healthy controls ( P = 0.005). Notably, NK cell cytotoxicity against K562 cells in the hydroxyurea or chronic transfusion patients was not significantly different from that in healthy controls. Conclusion: SCD is associated with increased NK cell function as well as increased NK cell numbers, which appears to be normalized with disease‐modifying therapy.